[go: up one dir, main page]

MX2020005543A - Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. - Google Patents

Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.

Info

Publication number
MX2020005543A
MX2020005543A MX2020005543A MX2020005543A MX2020005543A MX 2020005543 A MX2020005543 A MX 2020005543A MX 2020005543 A MX2020005543 A MX 2020005543A MX 2020005543 A MX2020005543 A MX 2020005543A MX 2020005543 A MX2020005543 A MX 2020005543A
Authority
MX
Mexico
Prior art keywords
sglt
inhibitor
combination
treatment
related diseases
Prior art date
Application number
MX2020005543A
Other languages
English (en)
Inventor
Marc Bellet
Marc Iglarz
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2020005543A publication Critical patent/MX2020005543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al compuesto aprocitentán, {5-(4-bromo-fenil)-6-[2-(5-bromopirimidin- 2-iloxi)-etoxi]-pirimid in-4-il}-sulfamida: (Ver formula) y su uso como antagonista del receptor de endotelina, en combinación con un inhibidor de SGLT-2. La invención se refiere adicionalmente a composiciones farmacéuticas que comprenden aprocitentán en combinación con dicho inhibidor de SGLT-2. La invención se refiere adicionalmente a dichas composiciones farmacéuticas que comprenden formas cristalinas de aprocitentán.
MX2020005543A 2017-11-30 2018-11-29 Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. MX2020005543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017081050 2017-11-30
PCT/EP2018/082947 WO2019106066A1 (en) 2017-11-30 2018-11-29 Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases

Publications (1)

Publication Number Publication Date
MX2020005543A true MX2020005543A (es) 2020-08-20

Family

ID=64606962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005543A MX2020005543A (es) 2017-11-30 2018-11-29 Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.

Country Status (21)

Country Link
US (2) US12144811B2 (es)
EP (1) EP3716979B1 (es)
JP (2) JP7404235B2 (es)
KR (1) KR20200094187A (es)
CN (1) CN111405899B (es)
AU (1) AU2018376263B2 (es)
BR (1) BR112020010831A2 (es)
CA (1) CA3083327A1 (es)
CL (1) CL2020001394A1 (es)
DK (1) DK3716979T3 (es)
EA (1) EA202091324A1 (es)
FI (1) FI3716979T3 (es)
IL (1) IL274943B2 (es)
LT (1) LT3716979T (es)
MA (1) MA51203A (es)
MX (1) MX2020005543A (es)
PH (1) PH12020550745A1 (es)
SG (1) SG11202004862XA (es)
TW (1) TWI809009B (es)
UA (1) UA127083C2 (es)
WO (1) WO2019106066A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907435PA (en) 2017-02-27 2019-09-27 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
WO2018231702A1 (en) 2017-06-13 2018-12-20 The Regents Of The University Of California Methods of improving cell-based therapy
US20230000816A1 (en) * 2019-11-07 2023-01-05 Increvet, Inc. Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals
CN114630668B (zh) * 2019-11-07 2024-02-27 苏州科睿思制药有限公司 一种Aprocitentan晶型及其制备方法和用途
BR112022010098A2 (pt) * 2019-11-26 2022-09-06 Actelion Pharmaceuticals Ltd Composição farmacêutica para o tratamento de doença vascular pulmonar e/ou disfunção cardíaca em pacientes submetidos à cirurgia de fontan
JP7624995B2 (ja) 2019-12-17 2025-01-31 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
PH12023550025A1 (en) 2020-07-10 2024-03-11 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
JOP20210087A1 (ar) * 2020-07-27 2023-01-30 Astrazeneca Ab طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技（台州）有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
AU2022340358A1 (en) * 2021-09-02 2024-01-04 Daewoong Therapeutics Inc. Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
AU2023276826A1 (en) 2022-05-22 2025-01-09 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
KR20250019676A (ko) 2022-05-25 2025-02-10 이도르시아 파마슈티컬스 리미티드 소듐 (5-(4-브로모페닐)-6-(2-((5-브로모피리미딘-2-일)옥시)에톡시)피리미딘-4-일)(술파모일)아미드의 결정질 형태
AU2023375521A1 (en) * 2022-11-10 2025-05-15 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors
KR102817359B1 (ko) * 2022-12-20 2025-06-11 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제
WO2025089933A1 (ko) * 2023-10-24 2025-05-01 주식회사 레드엔비아 Sglt-2 저해제 및 dpp-4 저해제를 포함하는 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
BRPI0116237B8 (pt) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
KR100701437B1 (ko) 2000-12-28 2007-03-30 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체 및 그 의약 용도
DE60237580D1 (de) * 2001-02-27 2010-10-21 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
ME00411B (me) 2003-08-01 2011-10-10 Tanabe Seiyaku Co Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
WO2005085265A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
WO2010138535A1 (en) 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) * 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
KR20160107344A (ko) 2014-01-31 2016-09-13 얀센 파마슈티카 엔.브이. 신장 장애 및 지방간 장애의 치료 및 예방 방법
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
US10174010B2 (en) * 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
KR20160132887A (ko) * 2014-04-04 2016-11-21 사노피 당뇨, 비만, 이상지질혈증 및 관련 장애 치료를 위한 gpr119 조절자로서의 치환된 인다논 화합물
US20170135981A1 (en) 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
CA2966756A1 (en) 2014-11-07 2016-05-12 Donald K. Kohan Methods of treating ckd using predictors of fluid retention
WO2017064679A1 (en) 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
SG11201907435PA (en) 2017-02-27 2019-09-27 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Also Published As

Publication number Publication date
CL2020001394A1 (es) 2020-10-16
JP2021504423A (ja) 2021-02-15
EP3716979A1 (en) 2020-10-07
EP3716979B1 (en) 2025-04-09
FI3716979T3 (fi) 2025-07-08
PH12020550745A1 (en) 2021-04-26
TW201924685A (zh) 2019-07-01
CN111405899B (zh) 2025-05-16
IL274943B1 (en) 2024-12-01
KR20200094187A (ko) 2020-08-06
UA127083C2 (uk) 2023-04-05
AU2018376263A1 (en) 2020-07-16
IL274943B2 (en) 2025-04-01
US12144811B2 (en) 2024-11-19
JP7635355B2 (ja) 2025-02-25
SG11202004862XA (en) 2020-06-29
CN111405899A (zh) 2020-07-10
IL274943A (en) 2020-07-30
JP2024037866A (ja) 2024-03-19
MA51203A (fr) 2020-10-07
TWI809009B (zh) 2023-07-21
AU2018376263B2 (en) 2024-10-31
US20250120973A1 (en) 2025-04-17
DK3716979T3 (da) 2025-06-30
US20210169881A1 (en) 2021-06-10
BR112020010831A2 (pt) 2020-11-10
EA202091324A1 (ru) 2020-10-05
JP7404235B2 (ja) 2023-12-25
WO2019106066A1 (en) 2019-06-06
CA3083327A1 (en) 2019-06-06
LT3716979T (lt) 2025-07-10

Similar Documents

Publication Publication Date Title
MX2020005543A (es) Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
MY186908A (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
HK1220355A1 (zh) Mk2抑制劑和其用途
MX2022001655A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
NZ725399A (en) Macrocylic pyrimidine derivatives
MX369799B (es) Derivados de piridina macrociclicos.
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
GEP20207130B (en) Imidazolone compounds as human neutrophil elastase inhibitors
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
HK1232076A1 (zh) 用於取代的1-苄基-3-(1-(异恶唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2，4-二酮的合成的改进方法
HK1236945A1 (en) Novel 2,5-substituted pyrimidines as pde inhibitors